Senseonics Reports at ATTD Glycemic Outcomes Across Adult Age Ranges with Real-World Eversense CGM Use
GERMANTOWN, Md.–(BUSINESS WIRE)–Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for adults with diabetes, presented data that demonstrated real-world use of the Eversense® CGM System across adult age ranges. Key International Consensus1 CGM targets were met in many adult patients with a greater percentage of users in the older age groups achieving targets and the younger adults showing promising results. The oldest age range met CGM target wear time, time in range, time below range and glucose management indicator (GMI – an estimator of A1C)2.
During an oral presentation at the Advanced Technologies and Treatments for Diabetes conference in Madrid, Spain, Senseonics presented real-world data on almost 600 Eversense users. The median transmitter wear time, mean sensor glucose, mean percent glucose management indicator, time spent in range, time spent in hyperglycemia and time spent in hypoglycemia were reported by 5 adult age groups2.
Key Findings
- Wear-time – All age groups met the recommended >70% CGM target wear time.
- Glucose Management Indicator (GMI) – Declined with age with >60 age group meeting the recommended target of 7%.
- Time in Range (TIR) – Increased with age with the ≥ 65 age group meeting the recommended target of >70% for TIR.
- Time in Hypoglycemia – All age groups were below or near the recommend target of 4 % time in hypoglycemia.
- Youngest age group (18-<25 years) – Showed promising glycemic outcomes with Eversense use with %GMI lower than observed in the T1D exchange for this age group, and with acceptable time in hypoglycemia.
- Conclusion – The Eversense real-world data showed promising glycemic results in all adult age ranges, but especially in those more than 60 years of age2.
|
Age |
SG mg/dL |
Percent Median Transmitter Wear Time per day |
%GMI |
Percent Time in Glucose Ranges | ||||
| 70-180 mg/dL |
< 54 mg/dL |
< 70 mg/dL |
> 180 mg/dL |
> 250 mg/dL |
||||
| 18-24 |
181.8 |
76.6 |
7.7 |
50.3 |
1.3 |
4.3 |
45.4 |
21.1 |
| 25-44 |
161.8 |
83.8 |
7.2 |
62.0 |
1.2 |
4.0 |
34.0 |
10.9 |
| 45-59 |
157 |
86.7 |
7.1 |
65.8 |
1.2 |
3.9 |
30.3 |
8.8 |
| >60 |
153.7 |
87.2 |
7.0 |
67.6 |
1.1 |
3.8 |
28.6 |
7.3 |
| ≥65 |
150.4 |
88.7 |
6.9 |
70.4 |
1.1 |
3.8 |
25.9 |
6.6 |
| Overall |
161.1 |
84.9 |
7.2 |
62.8 |
1.2 |
4.0 |
33.2 |
10.7 |
“This real-world data with the use of the Eversense CGM system demonstrated that glucose targets, including time in range and time in hypoglycemia, was achieved or nearly achieved across the adult age range,” explained Katherine Tweden, PhD, Vice President, Clinical Sciences at Senseonics. “This data provides more real-world evidence on the clinical value and benefit of Eversense CGM.”
The Eversense CGM System consists of a fluorescence-based sensor, a smart transmitter worn over the sensor to facilitate data communication, and a mobile app for displaying glucose values, trends and alerts. In addition to featuring the first long-term and first implantable CGM sensor, the system is also first to feature a smart transmitter that provides wearers with discreet on-body vibratory alerts for high and low glucose and can be removed, recharged and re-attached to the skin without discarding the sensor. Eversense users now have the freedom to make treatment decisions based on their Eversense readings. The sensor is inserted subcutaneously in the upper arm by a health care provider via a brief in-office procedure.
Patients who are interested in getting started on Eversense can sign up at www.eversensediabetes.com/get-started-today. Physicians, nurse practitioners or physician assistants interested in offering the Eversense CGM System for their patients can contact 844-SENSE4U (844-736-7348).
Reference
1 Battelino T, Danne T, Bergenstal R, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care 2019;42:1595–1597.
2 Katherine S Tweden, PhD, Patricia Sanchez, MS; Samanwoy Ghosh-Dastidar, PhD, Dr. Francine Kaufman, MD; The Effect of Age on Glycemic Outcomes in a Large Cohort of Eversense CGM System Adults Users. ATTD. 22 Feb 2020.
About Eversense
The Eversense® Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels in persons age 18 and older with diabetes for up to 90 days. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration twice per day, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense CGM System is a prescription device; patients should talk to their health care provider to learn more. For important safety information, see https://eversensediabetes.com/safety-info/.
About Senseonics
Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of transformational glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics’ CGM Systems, Eversense® and Eversense® XL, include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user’s smartphone.
Contacts
Senseonics Investor Contact
Lynn Lewis or Philip Taylor
Investor Relations
415-937-5406
investors@senseonics.com
Senseonics Media Contact:
Karen Hynes
Public Relations
619-206-9811
Karen.hynes@senseonics.com
